<DOC>
	<DOCNO>NCT00329030</DOCNO>
	<brief_summary>This study design Phase III , multicenter trial , compare progression-free survival ( PFS ) autologous hematopoietic stem cell transplantation use standard Rituxan plus BEAM transplant regimen versus regimen add Bexxar BEAM .</brief_summary>
	<brief_title>Rituxan v Bexxar When Combined With Carmustine , Etoposide , Cytarabine Melphalan ( BEAM ) With Autologous Hematopoietic Stem Cell Transplantation ( BMT CTN 0401 )</brief_title>
	<detailed_description>BACKGROUND : Bexxar ( Tositumomab Iodine I 131 Tositumomab ) radioimmunoconjugate demonstrate anti-lymphoma effect . This drug indicate treatment patient CD20 positive , relapsed refractory , low grade , follicular , transform non-Hodgkin 's lymphoma , include patient Rituximab-refractory non-Hodgkin 's lymphoma . Bexxar use several Phase I II transplant trial either alone combination high-dose chemotherapy treatment relapse non-Hodgkin 's lymphoma . The Phase I II trial combine Bexxar BEAM autologous hematopoietic stem cell transplantation demonstrate promising early result 80 % event-free survival relapse chemosensitive diffuse large B-cell non-Hodgkin 's lymphoma patient . The administration Rituxan mobilization condition regimen standard care transplant center . Therefore , primary endpoint study compare progression-free survival autologous hematopoietic stem cell transplantation chemotherapy-sensitive diffuse large B-cell lymphoma use Rituxan/BEAM versus Bexxar/BEAM pre-transplant conditioning . DESIGN NARRATIVE : All patient receive induction salvage chemotherapy indicate clinical circumstance achieve least partial response ( define protocol ) . There must 20 % less bone marrow involvement recent salvage therapy . Mobilization therapy may employ per institutional guideline , patient must receive one dose rituxan ( 375 mg/m^2 ) least within 4 week actual stem cell apheresis . Patients must adequate autograft ( target least 2.0 X 10^6 CD34+ cells/kg ; minimum 1.5 X 106 CD34+ cells/kg ) eligible protocol . Eligible patient randomize receive either : 1 ) Rituxan plus BEAM , Rituxan 375 mg/m^2 IV Days -19 -12 , Carmustine ( BCNU ) 300 mg/m^2 Day -6 , Etoposide 100 mg/m^2 Days -5 -2 , Cytarabine 100 mg/m^2 Days -5 -2 , Melphalan 140 mg/m^2 Day -1 follow ASCT ; , 2 ) Bexxar/BEAM dosimetric dose 5 mCi Bexxar Day -19 therapeutic dose calculate administer 75 cGy total body dose ( TBD ) Day -12 . Patients receive BCNU 300 mg/m^2 Day -6 , Etoposide 100 mg/m^2 Days -5 -2 , Cytarabine 100 mg/m^2 Days -5 -2 , Melphalan 140 mg/m^2 Day -1 follow ASCT . Patients follow 2 year post-transplant . Survival data , hematopoiesis data , incidence infection , mucositis assessment data , immune reconstitution data , toxicity data record report periodically BMT CTN Data Coordinating Center ( DCC ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis persistent recurrent REAL classification diffuse large Bcell lymphoma , composite lymphoma 50 % diffuse large Bcell lymphoma , mediastinal Bcell lymphoma Demonstration CD20+ least one histologic specimen 1880 year old time first registration Three few prior regimen chemotherapy entire course disease treatment ( include one induction chemotherapy 2 salvage chemotherapy ) ; monoclonal antibody therapy involve field radiation therapy count prior therapy Disease status primary induction failure , first relapse , second complete remission ; patient must chemosensitive disease demonstrate response induction salvage chemotherapy least partial response ( define protocol ) No 20 % bone marrow involvement Patients adequate organ function measure : Cardiac : American Heart Association Class I : Patients cardiac disease without result limitation physical activity ; ordinary physical activity cause undue fatigue , palpitation , dyspnea , anginal pain ; additionally , patient great 60 year age must leave ventricular ejection fraction rest least 40 % demonstrate MultiGated Acquisition Scan ( MUGA ) Hepatic : Bilirubin le 2.0 mg/dL ( except isolate hyperbilirubinemia attribute Gilbert syndrome ) alanine transaminase ( ALT ) aspartate transaminase ( AST ) less 3x upper limit normal Renal : Creatinine le 2.0 mg/dL creatinine clearance ( calculated creatinine clearance permit ) 40 mL/min ; hydronephrosis CT scan prior mobilization Pulmonary : Carbon Monoxide Diffusing Capacity ( DLCO ) , Volume forcibly exhale one second ( FEV1 ) , force vital capacity ( FVC ) least 45 % predict ( correct hemoglobin ) Autologous graft minimum least 1.5 X 10^6 CD34+ cells/kg ( target great 2.0 X 10^6 CD34+ cells/kg . Peripheral blood stem cell ( PBSC ) prefer ; however , PBSC mobilization fails , cell obtain institutional practice ( case bone marrow use transplantation , require CD34+ dose apply institutional practice total nucleate cell dose use ) . Initiate conditioning therapy within 3 month mobilization Signed informed consent Karnofsky performance score le 70 % Transformed follicular lymphoma Uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical improvement ) Prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ ; cancer treat curative intent le 5 year previously allow unless approve Medical Monitor Protocol Chair ; cancer treat curative intent le 5 year previously allow Pregnant ( positive Î²HCG ) breastfeeding ; patient population exclude due lack data use Bexxar patient pregnant breastfeed Seropositivity HIV ; patient population exclude due lack data use Bexxar HIV positive patient treatment regimens immunosuppressive patient population Fertile men woman unwilling use contraceptive technique time initiation mobilization sixmonths posttransplant Prior autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) Patients evidence myelodysplastic syndrome/acute myeloid leukemia ( MDS/AML ) abnormal cytogenetic analysis indicative MDS pretransplant bone marrow examination Patients prior severe reaction Rituxan Filgrastim ( GCSF ) . Patients severe reaction GCSF receive premedication control reaction exclude study . Patients receive prior radioimmunotherapy Patients know hypersensitivity murine protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Large B-Cell Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
</DOC>